Ryvu Therapeutics (FRA:9Y4) ROCE % : -31.63% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ryvu Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -31.63%.

Ryvu Therapeutics ROCE % Historical Data

The historical data trend for Ryvu Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics ROCE % Chart

Ryvu Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-24.43

-14.57

-34.56

-25.08

-24.10

Ryvu Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-19.79	-31.51	-22.57	-36.66	-31.63

Ryvu Therapeutics ROCE % Calculation

Ryvu Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-21.192	/	( ( (109.391 - 10.321)	+	(92.861 - 16.053) )	/ 2 )
	=	-21.192	/	( (99.07	+	76.808)	/ 2 )
	=	-21.192	/	87.939
	=	-24.10 %

Ryvu Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-22.692	/	( ( (93.654 - 20.544)	+	(92.855 - 22.46) )	/ 2 )
	=	-22.692	/	( ( 73.11	+	70.395 )	/ 2 )
	=	-22.692	/	71.7525
	=	-31.63 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Ryvu Therapeutics (FRA:9Y4) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ryvu Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RVU:Poland

Address

Leona Henryka Sternbacha 2, Krakow, POL, 30-394

Website

https://www.ryvu.com

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines